Proliferative Pituitary Lesions in Rats Treated with Salmon or Porcine Calcitonin

Abstract

Calcitonin, the serum calcium-lowering hormone, has been used in the treatment of hypercalcemia of malignancy and postmenopausal osteoporosis in humans for several years without any adverse effects. Recent studies in rats have indicated that calcitonin may be associated with morphologic effects on the pituitary. A large study was performed on 2 strains of rats, Sprague-Dawley (SD) and Fischer-344 (F-344), with 2 types of calcitonin, salmon-derived (sCT) and porcine-derived (pCT) calcitonin to evaluate possible effects on the pituitary. Sixteen groups of 42 male and 42 female SD or F-344 rats were given 0 (vehicle control), 1.25, 5.0, or 80.0 IU/kg/day of sCT or pCT, once daily, subcutaneously, for 1 yr.

An increased incidence of adenomas of the adenohypophysis was observed in male SD rats at all dose levels of sCT, female SD rats given 80 IU/kg/day of sCT, male SD rats at the high dose level of pCT, and male F-344 rats at the high dose level of sCT. Also, an increased incidence of total proliferative lesions, due mostly to an increased incidence of focal hyperplasia of the pars distalis, occurred in female F-344 rats given the high dose of sCT. These pituitary proliferations were histologically similar to those that occur spontaneously, and the incidences observed were comparable to those that could occur in rats on 2-yr or lifetime studies, indicating that the injection of calcitonin had decreased the latency period.

Keywords

Adenohypophysis adenocarcinoma adenoma hormone hypercalcemia osteoporosis SD rats F-344 rats

References

1. Azria M (1989). The Calcitonins: Physiology and Pharmacology S. Karger AG, Basel.

2. Black PMcL , Hsu DW , Klibanski A , Kliman B , Jameson L , Ridgway EC , Hedley-White ET , and Zervas NT (1987). Hormone production in clinically nonfunctioning pituitary adenomas. J. Neurosurg 66: 244–250.

3. Boorman GA , Heersche JNM , and Hollander CF (1974). Transplantable calcitonin-secreting medullary carcinomas of the thyroid in the WAG/Rij rat. J. Natl. Cancer Inst 53(4): 1011–1015.

4. Furth J and Clifton KH (1966). Experimental Pituitary Tumors. In: The Pituitary Gland, Vol. 2, G Harris and B Donovan (eds). Butterworths, London, pp. 460–497.

5. Furth J , Ueda G , and Clifton KH (1973). The pathophysiology of pituitaries and their tumors: Methodological advances. In: Methods in Cancer Research, Vol. 10, H Busch (ed). Academic Press, New York, pp. 201–277.

6. Griffith RW (1988). Carcinogenic potential of marketed drugs. J. Clin. Res. Drug Dev 2: 141–144.

7. Jameson JL , Weiss J , Polak JM , Childs GV , Bloom SR , Steel JH , Capen CC , Prentice DE , Fetter AW , and Langloss JM (1992). Glycoprotein hormone alpha-subunit producing pituitary adenomas in rats treated for one year with calcitonin. Am. J. Pathol 140(1): 75–84.

8. Osamura RY (1983). Pituitary tumors induced by estrogen, rat. In: Monographs on Pathology of Laboratory Animals. Vol. 1, Endocrine system. TC Jones , U Mohr , and RD Hunt (eds). Springer-Verlag, New York.

9. Kovacs K , Use G , Ryan N , McComb DJ , Horvath E , Chen HJ , and Walfish PG (1980). Pituitary prolactin cell hyperplasia. Hormone Res 12(2): 87–95.

10.

10. Lee AK , DeLellis RA , Blount M , Nunnemacher G , and Wolfe HJ (1982). Pituitary proliferative lesions in aging male Long-Evans rats. Lab. Invest 47(6): 595–602.

11.

11. Majka JA , Solleveld HA , Barthel CH , and Van Zwieten MJ (1990). Proliferative lesions of the pituitary in rats, E-2. In: Guides for Toxicologic Pathology STP/ARP/AFIP, Washington, DC, pp 1–8.

12.

12. McComb DJ , Kovacs K , Beri J , and Zak F (1984). Pituitary adenomas in old Sprague-Dawley rats: A histologic, ultrastructural and immunocytochemical study. J. Natl. Cancer Inst 73(5): 1143–1156.

13.

13. Russfield AB (1966). Tumors of Endocrine Glands and Secondary Sex Organs USHEW PHS Publication No. 1332, U.S. Government Printing Office, Washington, DC.

14.

14. Sandusky GE , VanPelt CS , Tood GC , and Wightman K (1988). An immunocytochemical study of pituitary adenomas and focal hyperplasia in old Sprague-Dawley and Fischer 344 rats. Toxicol. Pathol 16(3): 376–380.

15.

15. Turusov VS (ed) (1976). Pathology of Tumours in Laboratory Rats, Vol. I—Tumors of the Rat IARC Scientific Publication No. 6, pp. 201–238.

16.

16. Uchida K , Matsuzawa H , Kusano N , and Mutai M (1981). Spontaneous pituitary changes and their influence on mammary glands in SD female rats. Jikken Dobutsu 30(4): 421–433.

17.

17. Ward JM (1983). Background data and variations in tumor rates of control rats and mice. Prog. Exp. Tumor Res 26: 241–258.

18.

18. Yamagami T , Handa H , Takeuchi J , Munemitsu H , Aoki M , and Kato Y (1983). Rat pituitary adenoma and hyperplasia induced by caffeine administration. Surg. Neurol 20: 323–331.